Peritoneal carcinomatosis from colorectal cancer
By D. Jayne, S. Fook, C. Loi, F. Seow-Choen. British Journal of Surgery, 2002
830 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Surgery
View Paper: https://www.semanticscholar.org/paper/b0fd086f6b903c4b6aa5ca2cdb80c63049c4c6a8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- D. Elias
- F. Quénet
- V. Verwaal
- J. Lefèvre
- F. Gilly
- O. Glehen
- S. Bruin
- J. Chevalier
Citations in the corpus
- Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. (2010, background): “Natural history studies show that peritoneal carcinomatosis (PC) is uniformly fatal, with median survival (not exceeding) attaining 6 months.(3) For more than a decade, a handful of centers have pursued aggressive cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy (PIC), initiall”
- Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. (2009, background): “In a recent study of 3,019 colorectal cancer cases, the prevalence of PC was 11%.(2) The larger studies investigating the prognosis of isolated PC treated with chemotherapy included between 50 and 392 patients and showed median survival lasting from 5.”
- Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. (2004, background): “The three principal studies dedicated to the natural history of peritoneal carcinomatosis from colorectal cancer confirmed this poor prognosis, with a median survival ranging between 6 and 8 months and no 5-year survivors.(2,6,7) The carcinomatosis extent was found to be the principal prognostic ind”
- 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer (2008, background): “Peritoneal carcinomatosis is present in 10%of all colorectal cancer patients.(2) It can be seen as a step between local disease and systemic spread of a malignant disease.”